{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:23:30Z","timestamp":1760955810822},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Ablation therapy appears to be a reasonably safe and effective approach to obtain a significant treatment-free interval for a subset of patients with limited sites of metastatic disease for which systemic control can be obtained with six cycles of chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Metastatic sarcoma often becomes resistant to treatment by chemotherapy. There is sometimes prolonged stable disease from active chemotherapy that provides a window of opportunity for an intervention to prolong disease-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed a phase II study in patients with metastatic sarcoma who had been stable on six cycles of chemotherapy who then received ablation therapy to their residual disease. Histologies captured in this study included leiomyosarcoma, malignant peripheral nerve sheath tumor, pleiomorphic rhabdomyosarcoma, and myxoid liposarcoma. Sites ablated included lung metastases and retroperitoneal metastatic deposits. In this study, up to three lesions were ablated in any given interventional radiology session. After ablation, patients were not treated with any further therapy but were followed by surveillance imaging to determine progression-free rate (PFR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Although terminated early because of slow accrual, this study demonstrated a 3-month PFR of 75% for this cohort of eight patients treated with ablation performed after completion of six cycles of chemotherapy with stable disease. Median progression-free survival (PFS) was 19.74 months, and the median overall survival (OS) was not reached.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data are the first prospective study to suggest that ablation therapy in selected patients who are stable on chemotherapy can provide a significant progression-free interval off therapy and warrants further study in a randomized trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0536","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T21:16:06Z","timestamp":1519766166000},"page":"760-e76","source":"Crossref","is-referenced-by-count":14,"title":["A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy"],"prefix":"10.1093","volume":"23","author":[{"given":"Angela C.","family":"Hirbe","sequence":"first","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Jennings","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nael","family":"Saad","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Giardina","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqin","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shellie","family":"Berry","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqui","family":"Toeniskoetter","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[{"name":"School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"issue":"suppl 7","key":"2021122511044078900_onco12400-bib-0001","doi-asserted-by":"crossref","first-page":"vii265","DOI":"10.1093\/annonc\/mdq381","article-title":"Soft tissue sarcoma: From molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies","volume":"21","author":"Wardelmann","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122511044078900_onco12400-bib-0002","author":"American Cancer Society","year":"2017"},{"key":"2021122511044078900_onco12400-bib-0003","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaoncol.2016.0241","article-title":"Contemporary therapy for advanced soft-tissue sarcomas in adults: A review","volume":"2","author":"Pang","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122511044078900_onco12400-bib-0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/thx.46.10.727","article-title":"Results of thoracotomy in osteogenic sarcoma with pulmonary metastases","volume":"46","author":"Carter","year":"1991","journal-title":"Thorax"},{"key":"2021122511044078900_onco12400-bib-0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.athoracsur.2009.04.144","article-title":"Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival","volume":"88","author":"Blackmon","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"2021122511044078900_onco12400-bib-0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archsurg.142.1.70","article-title":"Benefit of surgical treatment of lung metastasis in soft tissue sarcoma","volume":"142","author":"Rehders","year":"2007","journal-title":"Arch Surg"},{"issue":"suppl 1","key":"2021122511044078900_onco12400-bib-0007","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ijsu.2008.12.028","article-title":"Microwave tumors ablation: Principles, clinical applications and review of preliminary experiences","volume":"6","author":"Carrafiello","year":"2008","journal-title":"Int J Surg"},{"key":"2021122511044078900_onco12400-bib-0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2214\/ajr.174.2.1740323","article-title":"Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance","volume":"174","author":"Goldberg","year":"2000","journal-title":"AJR Am J Roentgenol"},{"key":"2021122511044078900_onco12400-bib-0009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00261-004-0253-9","article-title":"A review of the general aspects of radiofrequency ablation","volume":"30","author":"Ni","year":"2005","journal-title":"Abdom Imaging"},{"issue":"suppl 1","key":"2021122511044078900_onco12400-bib-0010","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1148\/rg.25si055501","article-title":"Microwave ablation: Principles and applications","volume":"25","author":"Simon","year":"2005","journal-title":"Radiographics"},{"key":"2021122511044078900_onco12400-bib-0011","first-page":"90","article-title":"Percutaneous cryoablation techniques and clinical applications","volume":"16","author":"Tatli","year":"2010","journal-title":"Diagn Interv Radiol"},{"key":"2021122511044078900_onco12400-bib-0012","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1245\/s10434-011-1806-0","article-title":"Sarcoma lung metastases treated with percutaneous radiofrequency ablation: Results from 29 patients","volume":"18","author":"Palussi\u00e8re","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2021122511044078900_onco12400-bib-0013","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","article-title":"Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas","volume":"11","author":"Edmonson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122511044078900_onco12400-bib-0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/fon-2016-0498","article-title":"Advances and controversies in the management of soft tissue sarcomas","volume":"13","author":"Demetri","year":"2017","journal-title":"Future Oncol"},{"key":"2021122511044078900_onco12400-bib-0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021122511044078900_onco12400-bib-0016","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jso.20712","article-title":"Serum cytokine levels in response to hepatic cryoablation","volume":"95","author":"Osada","year":"2007","journal-title":"J Surg Oncol"},{"key":"2021122511044078900_onco12400-bib-0017","doi-asserted-by":"crossref","first-page":"160250","DOI":"10.1155\/2011\/160250","article-title":"More than just tumor destruction: Immunomodulation by thermal ablation of cancer","volume":"2011","author":"Haen","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"2021122511044078900_onco12400-bib-0018","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.ejca.2014.05.009","article-title":"Pulmonary metastasectomy for soft tissue sarcoma\u2013Report from a dual institution experience at the Medical University of Vienna","volume":"50","author":"Schur","year":"2014","journal-title":"Eur J Cancer"},{"key":"2021122511044078900_onco12400-bib-0019","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<675::AID-CNCR13>3.0.CO;2-Y","article-title":"Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients","volume":"77","author":"Geel","year":"1996","journal-title":"Cancer"},{"key":"2021122511044078900_onco12400-bib-0020","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1200\/EDBK_157450","article-title":"Local ablative therapies to metastatic soft tissue sarcoma","volume":"35","author":"Gronchi","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/760\/41915537\/oncolo_23_7_760.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/760\/41915537\/oncolo_23_7_760.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:05:24Z","timestamp":1640430324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/7\/760\/6439642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,2,27]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0536","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,2,27]]}}}